The FDA has announced that Apple's atrial fibrillation (AFib) detection tool on the Apple Watch is now qualified for use in clinical trials under its Medical Device Development Tools (MDDT) program. This qualification enables researchers to utilise the tool to detect arrhythmias or abnormal heartbeats, marking it as the first digital health tool to be qualified under the MDDT program. The feature is intended for use in clinical trials as a biomarker test to assess AFib burden, aiding in the evaluation of the safety and effectiveness of cardiac ablation devices while monitoring participants' weekly estimate of AFib burden.
This development comes amid a larger trend involving legal battles and regulatory challenges surrounding Apple's health-focused features. In February, Apple prevailed in a lawsuit against AliveCor over wearable heart-monitoring technology, although AliveCor plans to appeal the decision. Apple has also faced legal disputes regarding its blood oxygen sensors, with medtech company Masimo suing Apple for alleged employee poaching and theft of trade secrets. This led to a ban on selling and importing Apple smartwatches by the International Trade Commission, which President Biden failed to overturn, resulting in Apple modifying its watches to comply with the ban. The legal proceedings continue, highlighting the complexities surrounding technology and healthcare regulation.
Click here to read the original news story.